ImmunoCellular Therapeutics Signs Manufacturing Agreement with Formatech for Clinical Trial of ICT-121 Immunotherapy
26-Jun-2009 -
ImmunoCellular Therapeutics, Ltd. announced that the company has signed an agreement with Formatech, Inc. for the manufacture of IMUC’s cancer stem cell vaccine product candidate, ICT-121, for an upcoming clinical trial. The Phase I clinical trial of ICT-121 will target glioblastoma (brain ...
brain cancer
cancer stem cells
clinical trials
+2